vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Enphase Energy (ENPH). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $282.9M, roughly 1.0× Enphase Energy). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -2.6%, a 98.9% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -20.6%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -3.4%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Enphase Energy, Inc. is an American energy technology company headquartered in Fremont, California, that develops and manufactures solar micro-inverters, battery energy storage, and EV charging stations primarily for residential customers. Enphase was established in 2006 and is the first company to successfully commercialize solar micro-inverters, which convert the direct current (DC) power generated by solar panels into grid-compatible alternating current (AC) for use or export.
ACAD vs ENPH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $282.9M |
| Net Profit | $273.6M | $-7.4M |
| Gross Margin | 90.8% | 35.5% |
| Operating Margin | 6.1% | 54.0% |
| Net Margin | 96.3% | -2.6% |
| Revenue YoY | 9.4% | -20.6% |
| Net Profit YoY | 90.3% | -124.9% |
| EPS (diluted) | $1.61 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $282.9M | ||
| Q4 25 | $284.0M | $343.3M | ||
| Q3 25 | $278.6M | $410.4M | ||
| Q2 25 | $264.6M | $363.2M | ||
| Q1 25 | $244.3M | $356.1M | ||
| Q4 24 | $259.6M | $382.7M | ||
| Q3 24 | $250.4M | $380.9M | ||
| Q2 24 | $242.0M | $303.5M |
| Q1 26 | — | $-7.4M | ||
| Q4 25 | $273.6M | $38.7M | ||
| Q3 25 | $71.8M | $66.6M | ||
| Q2 25 | $26.7M | $37.1M | ||
| Q1 25 | $19.0M | $29.7M | ||
| Q4 24 | $143.7M | $62.2M | ||
| Q3 24 | $32.8M | $45.8M | ||
| Q2 24 | $33.4M | $10.8M |
| Q1 26 | — | 35.5% | ||
| Q4 25 | 90.8% | 44.3% | ||
| Q3 25 | 92.2% | 47.8% | ||
| Q2 25 | 92.2% | 46.9% | ||
| Q1 25 | 91.7% | 47.2% | ||
| Q4 24 | 91.6% | 51.8% | ||
| Q3 24 | 92.5% | 46.8% | ||
| Q2 24 | 92.5% | 45.2% |
| Q1 26 | — | 54.0% | ||
| Q4 25 | 6.1% | 6.5% | ||
| Q3 25 | 12.8% | 16.1% | ||
| Q2 25 | 12.2% | 10.2% | ||
| Q1 25 | 7.9% | 9.0% | ||
| Q4 24 | 59.1% | 14.3% | ||
| Q3 24 | 12.6% | 13.1% | ||
| Q2 24 | 12.6% | 0.6% |
| Q1 26 | — | -2.6% | ||
| Q4 25 | 96.3% | 11.3% | ||
| Q3 25 | 25.8% | 16.2% | ||
| Q2 25 | 10.1% | 10.2% | ||
| Q1 25 | 7.8% | 8.3% | ||
| Q4 24 | 55.4% | 16.2% | ||
| Q3 24 | 13.1% | 12.0% | ||
| Q2 24 | 13.8% | 3.6% |
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $1.61 | $0.29 | ||
| Q3 25 | $0.42 | $0.50 | ||
| Q2 25 | $0.16 | $0.28 | ||
| Q1 25 | $0.11 | $0.22 | ||
| Q4 24 | $0.86 | $0.46 | ||
| Q3 24 | $0.20 | $0.33 | ||
| Q2 24 | $0.20 | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $497.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $1.1B |
| Total Assets | $1.6B | $2.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $497.5M | ||
| Q4 25 | $177.7M | $1.5B | ||
| Q3 25 | $258.0M | $1.5B | ||
| Q2 25 | $253.6M | $1.5B | ||
| Q1 25 | $217.7M | $1.5B | ||
| Q4 24 | $319.6M | $1.6B | ||
| Q3 24 | $155.1M | $1.8B | ||
| Q2 24 | $177.1M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $917.3M | $995.0M | ||
| Q2 25 | $822.4M | $880.6M | ||
| Q1 25 | $765.2M | $810.7M | ||
| Q4 24 | $732.8M | $833.0M | ||
| Q3 24 | $577.2M | $931.4M | ||
| Q2 24 | $516.7M | $884.5M |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $1.6B | $3.5B | ||
| Q3 25 | $1.3B | $3.3B | ||
| Q2 25 | $1.2B | $3.2B | ||
| Q1 25 | $1.1B | $3.1B | ||
| Q4 24 | $1.2B | $3.2B | ||
| Q3 24 | $976.9M | $3.3B | ||
| Q2 24 | $914.1M | $3.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.11× | ||
| Q3 25 | — | 1.21× | ||
| Q2 25 | — | 1.37× | ||
| Q1 25 | — | 1.48× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.40× | ||
| Q2 24 | — | 1.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $102.9M |
| Free Cash FlowOCF − Capex | — | $83.0M |
| FCF MarginFCF / Revenue | — | 29.3% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $102.9M | ||
| Q4 25 | $-48.7M | $47.6M | ||
| Q3 25 | $74.3M | $13.9M | ||
| Q2 25 | $64.0M | $26.6M | ||
| Q1 25 | $20.3M | $48.4M | ||
| Q4 24 | $40.4M | $167.3M | ||
| Q3 24 | $63.2M | $170.1M | ||
| Q2 24 | $25.0M | $127.1M |
| Q1 26 | — | $83.0M | ||
| Q4 25 | — | $37.8M | ||
| Q3 25 | $73.9M | $5.9M | ||
| Q2 25 | — | $18.4M | ||
| Q1 25 | — | $33.8M | ||
| Q4 24 | — | $159.2M | ||
| Q3 24 | $63.2M | $161.6M | ||
| Q2 24 | — | $117.4M |
| Q1 26 | — | 29.3% | ||
| Q4 25 | — | 11.0% | ||
| Q3 25 | 26.5% | 1.4% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 9.5% | ||
| Q4 24 | — | 41.6% | ||
| Q3 24 | 25.2% | 42.4% | ||
| Q2 24 | — | 38.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.8% | ||
| Q3 25 | 0.1% | 2.0% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | 0.0% | 2.2% | ||
| Q2 24 | — | 3.2% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 1.23× | ||
| Q3 25 | 1.03× | 0.21× | ||
| Q2 25 | 2.40× | 0.72× | ||
| Q1 25 | 1.07× | 1.63× | ||
| Q4 24 | 0.28× | 2.69× | ||
| Q3 24 | 1.93× | 3.72× | ||
| Q2 24 | 0.75× | 11.73× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
ENPH
Segment breakdown not available.
